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PURPOSE. Structural retinal microvascular changes have been identified as risk markers of
diabetic retinopathy (DR). In order to estimate the retinal response of neuroprotective eye
drops, we aimed to evaluate the effect of topical retinal neuroprotection on retinal
microvascular changes in early DR.
METHODS. Patients with type 2 diabetes with no or early DR were randomized 1:1:1 to topical
treatment with placebo, brimonidine, or somatostatin in a 96-week prospective, phase II to
III, European multicenter trial. Retinal vascular calibers were measured semiautomatically in
digital fundus images by certified graders at baseline and follow-up and summarized as central
retinal arteriolar and venular equivalent (CRAE and CRVE).
RESULTS. Of 449 patients originally included, 297 completed the study with gradable retinal
images. Median age and duration of diabetes was 64.5 and 9.9 years, and 65.7% were male. At
baseline, Early Treatment Diabetic Retinopathy Study levels were 10 (no DR, 42.8%), 20
(minimal DR, 28.3%), and 35 (mild DR, 29.0%), and CRAE and CRVE did not differ between
groups. As opposed to patients with no or minimal DR at baseline, patients with mild DR in
the active groups developed a larger retinal arteriolar (brimonidine: þ6.2 lm, P ¼ 0.006;
somatostatin: þ7.2 lm, P ¼ 0.006) and venular (brimonidine: þ13.9 lm, P ¼ 0.01;
somatostatin: þ14.3 lm, P ¼ 0.0001) caliber in contrast to those in the placebo group.
CONCLUSIONS. Topical treatment with brimonidine and somatostatin causes retinal arteriolar
and venular dilation in patients with type 2 diabetes and preexisting early DR. Upcoming
studies should elaborate on the potential of these findings in arresting early DR.
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Diabetic retinopathy (DR) is the most common complicationin diabetes1 and among the leading cause of blindness
among working age adults in the Western world.2 DR has
traditionally been considered a microvascular disease, but
recent evidence has implicated retinal neurodegeneration as
an early event that may even precede vascular dysfunction.3,4
At present, retinal photocoagulation and intravitreal therapy
with vascular endothelial growth factor inhibitors are consid-
ered the gold standard treatment in DR5–7; but given the
invasive nature of the treatments, these are only considered in
patients with sight-threatening DR.
Topical treatment with a neuroprotective agent would be an
appealing approach to prevent or arrest DR at an early stage.
This concept has been supported by experimental data
demonstrating a prevention of retinal neurodegeneration by
topical administration of neuroprotective drugs.8–10 The
European Consortium for the Early Treatment of Diabetic
Retinopathy (EUROCONDOR) aimed to test the effect of
topically administered brimonidine and somatostatin on retinal
neurodysfunction in patients with type 2 diabetes with no or
early DR.11 The study reported that in patients with preexisting
retinal neurodysfunction, topical neuroprotection arrested
further loss of retinal function as measured by multifocal
electroretinography implicit time.12
It would also be important to investigate the structural
vascular effects of topical neuroprotective treatment. However,
as demonstrated by the Diabetes Control Complications Trial
(DCCT), even a strong systemic intervention like strict
glycemic regulation would take 3 years to affect the level of
DR.13 Hence, more subtle preclinical endpoints for vascular
dysfunction are needed. In this aspect, the retinal vascular
calibers, which can be measured noninvasively, have been
associated with14,15 and even predictive of sight-threatening
DR.16
In order to explore the effect of topical neuroprotection on
the retinal vasculature of patients with type 2 diabetes and early
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DR, the aim of the present study was to evaluate the result of 2
years of treatment with brimonidine and somatostatin on the
retinal vascular calibers in a randomized, clinical trial.
METHODS
Study Subjects
The EUROCONDOR [NCT01726075] was a European multi-
center, 96-week prospective, interventional, phase II to III,
randomized controlled clinical trial that aimed to evaluate the
effect of topical neuroprotection to arrest or prevent early
retinal neurodegeneration in DR.11 In a study including 11
European centers, a total of 449 patients were recruited and
randomized 1:1:1 to topical treatment twice daily (BID) with
placebo, brimonidine tartrate 0.2%, or somatostatin 0.1%.
Criteria of inclusion were: type 2 diabetes with no, minimal, or
mild DR (Early Treatment Diabetic Retinopathy Study [ETDRS]
levels 10, 20, or 35, respectively),17 duration of type 2 diabetes
for at least 5 years, and age between 45 and 75 years. Exclusion
criteria included previous retinal photocoagulation, retinal
degenerative diseases (i.e., glaucoma), and refractive error or
65 diopters or more, hazy ocular media, inadequate pupil
dilation, renal failure (creatinine >124 lm/L) or HbA1c >10%
(86 mmol/mol) in the previous 6 months.
For each patient, one eye was identified as the study eye by
a central reading center (Coimbra Ophthalmology Reading
Centre, Coimbra, Portugal), which also provided grading of the
level of DR at baseline and follow-up.
The study was approved and funded by the European
Commission Seventh Framework Program (Grant Agreement
No. FP7–278040). At all centers, the study was conducted in
accordance with the tenets of the Declaration of Helsinki with
approvals of the local scientific ethnical committees and
written informed consent from all patients.
Retinal Vascular Caliber Analysis
Mydriatic cameras (TRC-50IA, -50IX, -50EX, -50DX, -50DX Type
IA, or NW6S; Topcon Corp., Tokyo, Japan) or a fundus camera
(FF450 PLUS IR; Carl Zeiss Meditec, Jena, Germany) were used
to capture 308 to 358 modified ETDRS-field 1 images including
the optic disc of the study eye. These were subsequently used
for retinal vascular caliber measurements.18 Images were
analyzed by IVAN (Department of Ophthalmology and Visual
Science, University of Wisconsin, Madison, WI, USA), which is
a semiautomatic software program that has previously been
validated.19
The optic disc is automatically detected by the software,
and vessel calibers are traced in a zone of 0.5 to 1.0 disc-
diameters from the optic disc margin. After manual adjustment
by the grader, retinal vascular calibers are summarized into the
central retinal arteriolar and venular equivalent (CRAE and
CRVE) according to the ‘‘Big 6-formula’’ that includes the six
largest arterioles and venules.20
At baseline, images were graded by a single, trained grader
(UFO), and at follow-up images were graded at a certified
retinal image grading center (Yamagata University, Yamagata,
Japan).
Clinical Examinations
Patients were treated in each eye with 1 drop BID (placebo or
somatostatin 0.1% or brimonidine tartrate 0.2%) and followed
for 96 weeks with comprehensive ophthalmic examinations
every 24 weeks as previously described.12
Of 449 patients invited at baseline, 297 (66.1%) completed
the study with gradable retinal images at baseline and follow-
up. Of the 153 patients that were not included in the present
study, reasons for noninclusion included dropout during study
(n ¼ 109), lack of retinal images at follow-up (n ¼ 17), and
nongradable retinal images at baseline (n¼ 10) or follow-up (n
¼ 17). Among nonparticipants, there was a higher number of
patients allocated to treatment with brimonidine (43.4% vs.
28.6%, P ¼ 0.009), but otherwise participants and nonpartic-
ipants did not differ according to age, duration of diabetes, sex,
glycemic regulation, blood pressure, body mass index, level of
DR, CRAE, or CRVE (Table 1).
Statistical Methods
Descriptive statistics were calculated for all parameters.
Continuous data are presented as median (with range), and
categoric data are given as percentage. Development in retinal
vascular calibers and level of DR were given as differences
between follow-up and baseline.
To test for differences in unpaired, continuous data, we
used nonparametric tests including Mann-Whitney U test (two
groups), Kruskal-Wallis test (multiple, nonordered groups) and
Cuzick’s test for trend (multiple, ordered groups). Wilcoxon
matched-pairs signed-rank test was used to test for differences
between baseline and follow-up in matched paired of
observations. Finally, v2 test was used to test for differences
in categorical data.
Statistical analysis was performed by statistical software
(Stata 15.1; StataCorp LLC, College Station, TX, USA), and P
values below 0.05 were considered statistically significant.
RESULTS
Among the 297 participants of the study, median age and
duration of diabetes at baseline was 64.5 and 9.9 years, and
65.7% were male. Median levels of HbA1c, blood pressure, and
body mass index were 7.0%, 135/78 mm Hg and 30.0 kg/m2,
respectively. Baseline ETDRS levels of DR were 10 (42.8%), 20
(28.3%), or 35 (29.0%), and CRAE and CRVE was 146.6 lm and
214.8 lm, respectively.
Number of patients in each treatment group were 108
(36.4%), 85 (28.6%), and 104 (35.0%) for placebo, brimonidine,
and somatostatin, respectively. Among treatment groups,
patients did not differ at baseline according to age, sex,
duration of diabetes, HbA1c, blood pressure, body mass index,
CRAE (146.7 lm, 147.1 lm, and 145.2 lm, P¼ 0.68) or CRVE
(215.6 lm, 212.7 lm, and 215.7 lm, P ¼ 0.89; Table 2).
Likewise, there was no difference in CRAE according to
baseline level of DR (level 10, 144.1 lm; level 20, 147.7 lm;
level 35, 148.2 lm; P¼ 0.10), but there was a trend toward a
higher CRVE for patients with increasing levels of DR (level 10,
213.7 lm; level 20, 214.4 lm; level 35, 216.1 lm; P¼ 0.056).
During 24 months of topical treatment, there was a median
increase of CRAE and CRVE of 1.0 lm (P¼ 0.01) and 2.6 lm (P
¼ 0.0002) in the overall population. Changes in retinal vascular
calibers depended on baseline level of DR and treatment group
(Table 3). Overall, patients with higher levels of DR at baseline
developed a higher CRAE (level 10,1.0 lm; level 20,1.0 lm;
level 35, þ6.1 lm; P¼ 0.001; Fig. 1) and CRVE (level 10, þ1.3
lm; level 20,þ1.4 lm; level 35,þ10.3 lm; P¼ 0.001; Fig. 2) at
follow-up. Even though there was no general difference
between treatment groups in the alteration of CRAE (placebo,
þ1.8 lm; brimonidine, þ1.9 lm; somatostatin, 0.2 lm; P ¼
0.98) or CRVE (placebo, þ3.7 lm; brimonidine, þ1.3 lm;
somatostatin,þ2.4 lm; P¼ 0.78), it was demonstrated that the
development of wider retinal vascular calibers in higher levels
of DR depended on the treatment regimen; patients treated
with placebo did not increase in CRAE (P¼ 0.17) or CRVE (P¼
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0.56) with increasing baseline levels of DR. In contrast, there
was a DR-dependent arteriolar widening in patients treated
with somatostatin (P¼ 0.01), and a venular dilation in patients
treated with brimonidine (P ¼ 0.048) and somatostatin (P ¼
0.01).
At follow-up, level of DR improved, remained unchanged
and worsened in 28.0% (n¼ 83), 65.7% (n¼ 195), and 6.4% (n
¼ 19) patients, respectively. There were no differences in rates
of improvement, unchanged conditions, and DR worsening
between patients in the different treatment groups (placebo,
28.7% vs. 66.7% vs. 4.6%; brimonidine, 25.9% vs. 63.5% vs.
10.6%; somatostatin, 28.9% vs. 66.4% vs. 4.8%, P ¼ 0.47). Of
patients with a potential to improve or worsen more than one
level of DR from baseline, this was only found in 23.3% (20 of
86 with ETDRS 35 at baseline) and 1.2% (2 of 127 with ETDRS
10 at baseline), respectively. There was no difference in CRAE
(P ¼ 0.51) or CRVE (P ¼ 0.75) when patients were compared
according to development in DR during the study.
DISCUSSION
In a 96-week, prospective, randomized trial evaluating the
retinal effect of topical neuroprotective treatment, we con-
cluded that in patients with preexisting mild DR, brimonidine
and somatostatin both induced retinal vascular dilation as
opposed to placebo.
Our results are in contrast with the earlier conception that
topical treatment is inadequate to induce a vascular retinal
effect given the corneal barrier and the intraocular distance
between the anterior and posterior part of the eye. However,
TABLE 1. Baseline Characteristics in Patients With and Without Gradable Images*
Patient Characteristics
Completed Study
With Gradable
Retinal Images
Did Not Include
or With
Ungradable Images P Value
Patients, n 297 153
Age, y 64.5 (45.4–76.0) 63.7 (45.8–75.7) 0.46
Duration of diabetes, y (range) 9.9 (4.9–40.4) 10.7 (4.6–31.7) 0.18
Male sex, % 65.7 67.1 0.76
HbA1c, % (range) 7.0 (5.0-10.0) 7.0 (5.4–10.8) 0.86
Systolic blood pressure, mm Hg (range) 135 (95–183) 135 (98–186) 0.34
Diastolic blood pressure, mm Hg (range) 78 (55–103) 77 (50–115) 0.87
Body mass index, kg/m2 (range) 30.1 (20.1–53.9) 29.7 (19.7–53.7) 0.67
Level of DR, % 0.91
10 42.8 41.3
20 28.3 25.9
35 29.0 32.9
Treatment group, % 0.009†
Placebo 36.4 28.0
Brimonidine 28.6 43.4
Somatostatin 35.0 28.7
Central retinal arteriolar equivalent, lm (range) 146.6 (110.4–184.6) 146.9 (111.6–196.0) 0.66
Central retinal venular equivalent, lm (range) 214.8 (160.0–283.9) 217.1 (162.3–290.8) 0.99
Data presented as median (with minimum and maximum) or percent. Level of DR defined according to Early Treatment Diabetic Retinopathy
Study scale.
* For patients that completed the study with gradable retinal images at baseline and follow-up as compared to those that did not complete the
study or had ungradable retinal images at baseline or follow-up.
† Statistically significant (P < 0.05).
TABLE 2. Baseline Characteristics of Study Patients*
Patient Characteristics Placebo Brimonidine Somatostatin P Value
Patients, n 108 85 104
Age, y (range) 63.9 (46.8–76.0) 64.4 (50.4–74.3) 64.6 (45.4–75.3) 0.73
Duration of diabetes, y (range) 9.8 (5.4–37.3) 9.9 (5.3–40.4) 10.0 (4.9–30.6) 0.78
Male sex, % 68.5 65.9 62.5 0.65
HbA1c, % (range) 7.0 (5.0–10.0) 7.1 (5.4–10.0) 7.0 (5.4–9.7) 0.59
Systolic blood pressure, mm Hg (range) 135 (104–180) 138 (95–164) 150 (108–183) 0.77
Diastolic blood pressure, mm Hg (range) 80 (55–103) 78 (58–103) 75 (55–101) 0.26
Body mass index, kg/m2 (range) 29.8 (20.4–48.5) 29.8 (20.1–53.9) 30.4 (21.6–47.7) 0.87
Level of DR, % 0.70
10 44.4 37.7 45.2
20 28.7 25.9 26.0
35 26.9 31.8 28.9
Central retinal arteriolar equivalent, lm (range) 146.7 (122.7–183.5) 147.1 (114.2–183.5) 145.2 (110.4–184.6) 0.68
Central retinal venular equivalent, lm (range) 215.6 (160.0–276.0) 212.7 (174.1–265.6) 215.7 (162.8–283.9) 0.89
Data presented as median (with minimum and maximum) or per cent. Level of DR defined according to Early Treatment Diabetic Retinopathy
Study scale.
* For the 297 patients that completed the study with gradable retinal images at baseline and follow-up according to treatment group.
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this concept has been challenged by animal studies8,9 as well as
a 1-week trial by Tilma and Bek21 demonstrating retinal
arteriolar narrowing in 22 patients with type 1 diabetes treated
with topical latanoprost. In the present study, we demonstrate
a long-term effect of the retinal vasculature by two indepen-
dent neuroprotective drugs, even though the study period
might not have been long enough to arrest or prevent
development of DR. As indicated by the DCCT in type 1
diabetes, this would likely take at least 3 years, which was the
reason that EUROCONDOR was designed to study surrogate
markers of early vascular and neurogenic dysfunction.
Retinal vascular calibers have been identified as early
biomarkers of retinal structural dysfunction in diabetes.14,22,23
In a 16-year prospective study of patients with type 1 diabetes,
Broe et al.16 reported that a 10-lm retinal arteriolar narrowing
and venular dilation independently predicted long-term prolif-
erative DR, nephropathy, and peripheral neuropathy with odds
ratios of 1.4 to 3.0. Likewise, the Wisconsin Epidemiological
Study of Diabetic Retinopathy found that a 10 lm retinal
venular (but not arteriolar) dilation in 4 years, associated with a
higher risk of various DR-endpoints in the following 6 years.24
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FIGURE 1. Development in CRAE during 96 weeks of topical treatment
according to Early Treatment Diabetic Retinopathy Study levels of DR
at baseline. There was a higher development with more advanced DR
(level 10, 1.0 lm; level 20, 1.0 lm; level 35, þ6.1 lm; P¼ 0.001).
FIGURE 2. Development in CRVE during 96 weeks of topical treatment
according to Early Treatment Diabetic Retinopathy Study levels of DR
at baseline. There was a higher development with more advanced DR
(level 10, þ1.3 lm; level 20, þ1.4 lm; level 35, þ10.3 lm; P¼ 0.001).
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Both of these studies identify retinal vascular dilation as a risk
factor of DR-progression, which might seem in opposition with
our findings of a retinal vascular dilation in response to
neuroprotective treatment. However, comparisons are difficult
given that most patients in the studies by Broe et al.16 and
Klein et al.24 had no or minimal DR, whereas our results were
found in patients with preexisting mild DR at baseline. In
addition, Broe et al.16 only evaluated patients with type 1
diabetes as opposed to type 2 diabetes in the EUROCONDOR.
In the EUROCONDOR, we have previously reported that
there was no association between baseline levels of DR and
CRAE, but patients with moderate NPDR had a higher CRVE
(ETDRS 10, 214.5 lm; ETDRS 20, 213.2 lm; ETDRS 35, 216.6
lm; P¼ 0.04) although this could not be considered clinically
significant.18 Noticeably, in the present study only patients
with preexisting DR developed arteriolar and venular widen-
ing, and we demonstrate that this was influenced by the
topically administered agent. This is in alignment with the
principal findings of the EUROCONDOR which report that
neuroprotective treatment was only effective in patients with
preexisting retinal neurodysfunction.12 In particular, patients
with mild NPDR in both neuroprotective groups had a retinal
venular dilation of more than three times of that in the placebo
group. This effect size is likely to be clinically relevant. To
illustrate, the retinal venular dilation induced by topical
neuroprotection in our patients with preexisting mild DR
(þ13.9–14.3 lm) has the same size as the difference in CRVE
between an average 50- and 85-year-old person, in which the
former would be 13 lm wider.25
There is no clear mechanistic explanation of the topically
induced vascular dilation in patients with moderate NPDR, but
it could potentially be given by compensatory increased blood
flow to prevent peripheral nonperfusion which is strongly
associated with DR progression26 and poor treatment out-
come.27 Another potential explanation was proposed by
Ludovico et al.28 that demonstrated retinal vasodilation in
50% of patients with early diabetes and suggested that a lack of
vasodilation could be a harmful response. While hypoxia
induces retinal vasodilation in healthy eyes,29 lack of dilation in
diabetes can be caused by basement membrane thickening or
pericyte loss, which may lead to capillary dropout and
closure.30 One of the main reasons of the lack of vasodilation
in nontreated diabetic eyes can be attributed to the impairment
of the neurovascular unit, which prevents vasodilation, thus
impeding to adapt to the higher metabolic demands that exist
in the diabetic retina. Consequently, the neuroactive drugs
used in EUROCONDOR may have a favorable effect by
improving the neurovascular unit function. This effect results
in vasodilation and, therefore, improved autoregulation and
delayed capillary dropout. However, with the data at hand, we
cannot conclude if treatment-induced retinal vascular dilation
in mild DR is a specific consequence of topical neuroprotec-
tion with brimonidine and somatostatin, or if this would also
be observed with other interventions.
It can be difficult to compare retinal vascular calibers
between studies. For instance, Drobnjak et al.31 reported
median CRAE and CRVE of 163.3 and 251.0 lm, which were
substantial higher than the baseline finding of our study (146.6
and 214.8 lm).31 Unbalances might be explained by differenc-
es in ages, populations, methodology, and by the fact that
diabetes was only present in a subset of patients in the study by
Drobnjak et al.31
Strengths of the present study include the prospective,
randomized design and the long follow-up with repeated
measurements over time. On the other hand, limitations should
be acknowledged. First, we did not include retinal flow
measurements which could have provided additional informa-
tion regarding retinal perfusion. Second, there was a higher
than expected dropout which may limit the generalizability of
the results. Third, retinal vascular calibers were measured by
different graders at baseline and follow-up.
In conclusion, the present study demonstrated retinal
vascular dilation induced by long-term topical neuroprotection
in 297 patients with type 2 diabetes and mild DR. The concept
that eye drops may induce retinal vascular changes would be
appealing in order to prevent or delay DR in the early phases,
and upcoming prospective studies would be needed to
translate this into clinical care.
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